Surveillance of influenza B severe hospitalized cases during 10 seasons in Catalonia: Does the lineage make a difference?
Authors:
- Núria TornerNTNúria Torner
- the PIDIRAC Surveillance of Hospitalized Cases of Severe Influenza in Catalonia Working GroupTGthe PIDIRAC Surveillance of Hospitalized Cases of Severe Influenza in Catalonia Working Group
Open Access
- 4 June 2022
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (9) , 4417-4424
Abstract
Influenza B viruses circulate in two lineages (B/Victoria and B/Yamagata). Although classically affecting children, recently it has shown a high rate of infection and increased hospitalization in the elderly. To describe and analyze the clinical and epidemiological characteristics of severe hospitalized laboratory‐confirmed influenza B virus (SHLCI‐B) cases in Catalonia associated with mismatch from Influenza B virus strain included in the trivalent influenza vaccine (TIV). SHLCI‐B was registered by the influenza sentinel surveillance system of Catalonia (PIDIRAC) during ten surveillance seasons from 2010 to 2020. Variables age, comorbidities, and vaccination status were recorded. Vaccine effectiveness was estimated as (1‐OR) for intensive care unit (ICU) admission. Statistical significance was established at p < 0.05. A total of 1159 SHLCI‐B were registered, of these 68.2% (791) corresponded to the 2017–2018 season; 21.8% (253) were admitted to ICU and 13.8% (160) were exitus; 62.5% (725) cases occurred in those aged >64 years; most frequent risk factor was cardiovascular disease (35.1%, 407) followed by chronic pulmonary obstructive disease‐COPD (24.6%, 285) and diabetes (24.1%, 279). In four seasons, the predominant circulating lineage was B/Victoria, in two seasons the B/Yamagata lineage and four seasons had no IBV activity. Four seasons presented discordance with the strain included within the TIV. Vaccine effectiveness (VE) to prevent ICU admission was 31% (95% confidence interval [CI]: 4%–51%; p = 0.03); being 29% (95% CI: −3% to 51%) in discordant and 43% (95% CI:−43% to 77%) in concordant seasons. Significant differences were observed in the number of affected aged > 64 years (odds ratio [OR] = 2.5; 95% CI: 1.9–3.4; p < 0.001) and in patients with heart disease (OR = 2.40 95% CI: 1.7–3.4; p < 0.001), COPD (OR = 1.6 95% CI: 1.1–2.3; p = 0.01), and diabetes (OR = 1.5 95% CI: 1.1–2.1; p = 0.04) between discordant and concordant seasons. The increase in hospitalization rate in people> 64 years of age and those presenting comorbidities in seasons with circulating influenza B virus belonging to a lineage discordant with the strain included in the TIV and the decrease of VE to prevent ICU admissions evidence the vital need to administer the quadrivalent influenza vaccine regardless of the findings of predominant circulation in the previous season.Keywords
This publication has 24 references indexed in Scilit:
- A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza controlHuman Vaccines & Immunotherapeutics, 2017
- Hospitalization for Influenza A Versus BPediatrics, 2016
- Epidemiological and Virological Characterization of Influenza B Virus InfectionsPLOS ONE, 2016
- Epidemiological, Clinical and Virological Characteristics of Influenza B Virus from Patients at the Hospital Tertiary Care Units in Bangkok during 2011-2014PLOS ONE, 2016
- Virological surveillance of influenza and other respiratory viruses during six consecutive seasons from 2006 to 2012 in Catalonia, SpainClinical Microbiology and Infection, 2016
- A comprehensive review of the epidemiology and disease burden of Influenza B in 9 European countriesHuman Vaccines & Immunotherapeutics, 2016
- Epidemiological and virological characteristics of influenza B: results of the Global Influenza B StudyInfluenza and Other Respiratory Viruses, 2015
- Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virusHuman Vaccines & Immunotherapeutics, 2015
- The rationale for quadrivalent influenza vaccinesHuman Vaccines & Immunotherapeutics, 2012
- Typing (A/B) and subtyping (H1/H3/H5) of influenza A viruses by multiplex real-time RT-PCR assaysJournal of Virological Methods, 2008